Indian ethics code: will industry self-regulation suffice?
This article was originally published in Scrip
The Medical Council of India's (MCI) efforts to regulate the symbiotic relationship between drug companies and physicians have brought to the fore the sticky issue of whether industry itself needs more regulation or whether self-regulation would suffice. Scrip's India Editor Anju Ghangurde takes a look at some of the issues.
You may also be interested in...
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.